Cementos Bio Bio S.A. (SNSE: CEMENTOS)
710.00
+5.00 (0.71%)
Sep 10, 2024, 3:43 PM CLT
Cementos Bio Bio Income Statement
Financials in millions CLP. Fiscal year is January - December.
Millions CLP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 360,652 | 348,984 | 334,004 | 289,468 | 242,586 | 268,614 | Upgrade
|
Revenue Growth (YoY) | 3.19% | 4.49% | 15.39% | 19.33% | -9.69% | 2.30% | Upgrade
|
Cost of Revenue | 220,913 | 219,384 | 228,479 | 186,287 | 146,484 | 158,919 | Upgrade
|
Gross Profit | 139,740 | 129,600 | 105,525 | 103,181 | 96,102 | 109,694 | Upgrade
|
Selling, General & Admin | 97,075 | 94,713 | 94,110 | 86,095 | 73,039 | 89,738 | Upgrade
|
Operating Expenses | 97,075 | 94,713 | 94,110 | 86,095 | 73,039 | 89,738 | Upgrade
|
Operating Income | 42,665 | 34,887 | 11,415 | 17,086 | 23,062 | 19,957 | Upgrade
|
Interest Expense | -12,654 | -14,353 | -11,141 | -3,561 | -4,038 | -5,965 | Upgrade
|
Interest & Investment Income | 571.8 | 1,210 | 1,063 | 598.99 | 285.22 | 923.36 | Upgrade
|
Currency Exchange Gain (Loss) | 2,628 | 434.34 | -1,311 | 1,425 | -1,248 | -3.51 | Upgrade
|
Other Non Operating Income (Expenses) | 6,974 | 3,574 | 1,954 | 2,114 | 385.14 | 727.79 | Upgrade
|
EBT Excluding Unusual Items | 40,185 | 25,752 | 1,980 | 17,662 | 18,447 | 15,639 | Upgrade
|
Gain (Loss) on Sale of Assets | 466.61 | 556.51 | 3,427 | 8,655 | 1,178 | 745.46 | Upgrade
|
Asset Writedown | -985.44 | -584.07 | -2,550 | -988.27 | -3,478 | -3,404 | Upgrade
|
Other Unusual Items | - | - | - | 685.41 | 43.04 | 2,063 | Upgrade
|
Pretax Income | 40,562 | 26,622 | 5,635 | 33,911 | 16,263 | 15,044 | Upgrade
|
Income Tax Expense | 7,689 | 3,812 | -4,926 | 6,885 | 2,351 | 2,095 | Upgrade
|
Earnings From Continuing Operations | 32,873 | 22,809 | 10,561 | 27,026 | 13,912 | 12,949 | Upgrade
|
Minority Interest in Earnings | 28.63 | -12.25 | -1.13 | -146.9 | -149.47 | 155.2 | Upgrade
|
Net Income | 32,901 | 22,797 | 10,560 | 26,879 | 13,763 | 13,104 | Upgrade
|
Net Income to Common | 32,901 | 22,797 | 10,560 | 26,879 | 13,763 | 13,104 | Upgrade
|
Net Income Growth | 104.56% | 115.88% | -60.71% | 95.30% | 5.03% | -33.73% | Upgrade
|
Shares Outstanding (Basic) | 265 | 264 | 264 | 264 | 264 | 264 | Upgrade
|
Shares Outstanding (Diluted) | 265 | 264 | 264 | 264 | 264 | 264 | Upgrade
|
Shares Change (YoY) | 0.17% | - | - | - | - | - | Upgrade
|
EPS (Basic) | 124.31 | 86.28 | 39.97 | 101.73 | 52.09 | 49.59 | Upgrade
|
EPS (Diluted) | 124.31 | 86.28 | 39.97 | 101.73 | 52.09 | 49.59 | Upgrade
|
EPS Growth | 104.21% | 115.88% | -60.71% | 95.30% | 5.03% | -33.73% | Upgrade
|
Free Cash Flow | 33,846 | 23,291 | 9,374 | 3,860 | 24,226 | 17,780 | Upgrade
|
Free Cash Flow Per Share | 127.87 | 88.15 | 35.48 | 14.61 | 91.69 | 67.29 | Upgrade
|
Dividend Per Share | 23.000 | 36.000 | 12.000 | 48.000 | 42.000 | 16.000 | Upgrade
|
Dividend Growth | -8.00% | 200.00% | -75.00% | 14.29% | 162.50% | -56.76% | Upgrade
|
Gross Margin | 38.75% | 37.14% | 31.59% | 35.64% | 39.62% | 40.84% | Upgrade
|
Operating Margin | 11.83% | 10.00% | 3.42% | 5.90% | 9.51% | 7.43% | Upgrade
|
Profit Margin | 9.12% | 6.53% | 3.16% | 9.29% | 5.67% | 4.88% | Upgrade
|
Free Cash Flow Margin | 9.38% | 6.67% | 2.81% | 1.33% | 9.99% | 6.62% | Upgrade
|
EBITDA | 53,502 | 48,082 | 24,159 | 30,270 | 34,832 | 30,633 | Upgrade
|
EBITDA Margin | 14.83% | 13.78% | 7.23% | 10.46% | 14.36% | 11.40% | Upgrade
|
D&A For EBITDA | 10,837 | 13,195 | 12,744 | 13,184 | 11,770 | 10,676 | Upgrade
|
EBIT | 42,665 | 34,887 | 11,415 | 17,086 | 23,062 | 19,957 | Upgrade
|
EBIT Margin | 11.83% | 10.00% | 3.42% | 5.90% | 9.51% | 7.43% | Upgrade
|
Effective Tax Rate | 18.96% | 14.32% | - | 20.30% | 14.45% | 13.93% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.